A New Way to Fight HIV: Using the Body's Own Immune Cells

Scientists have announced early success with a new approach to treating HIV. Instead of relying on daily medications, researchers are taking immune cells from HIV patients, training them in the lab to recognize and attack the virus, and putting them back in the body. The early results suggest this approach could keep the virus under control without pills—something the HIV research community has pursued for decades.

The company Caring Cross presented this data at a medical conference in Boston. Their treatment, called duoCAR-T therapy, works by extracting a patient's own immune cells (T cells), modifying them genetically to recognize HIV, and then infusing them back. It requires only a single treatment.

Early Results Show Promise

The trial revealed something striking: two patients treated with the modified immune cells experienced strong viral suppression—one for nearly a year and another for nearly two years—while not taking their usual HIV medications.

This is preliminary data from just a few patients, but doctors involved in the trial called the results "especially compelling." The approach appears to work best in patients who started HIV treatment early in their infection.

A clinical trial is currently underway (registered under NCT06252402) testing these engineered cells.

Other Research Teams Are Pursuing Similar Ideas

Caring Cross is not alone. Research groups elsewhere are exploring related approaches. One team published results in Nature showing that engineered immune cells called M10 CAR-T could suppress viral rebound in a majority of patients. In that study of 18 patients, the engineered cells triggered significant suppression of viral rebound in 74.3% of infusions, with viral loads dropping an average of 67.1%. Half the patients showed sustained reduction in HIV levels over 150 days of observation.

Another research group has begun testing engineered immune cells that target a different part of the virus, expanding the range of biological targets researchers are trying to attack.

How This Works: The Basic Science

Here's the key idea: unlike cancers, which are made of the body's own cells gone wrong, HIV hides inside your immune cells. So engineered immune cells have to find infected cells in the body and destroy them while the virus sits dormant inside the cell's DNA.

Think of it like training security guards to spot and remove intruders who are hiding inside buildings they now occupy. The guards themselves are human—built from your own immune system—so the body is less likely to reject them.

The specific preparation given to patients before the Caring Cross treatment appears to matter. Patients who received special conditioning—a preparative treatment—had better viral suppression than those who did not, though the details of that preparation have not been publicly disclosed.

What Comes Next

The field is still in early stages. These are small trials with only a handful of patients, so the results need to be confirmed in larger studies with more people.

One important consideration: the patients in these trials were carefully selected. They were already taking HIV medication and had started treatment early, meaning their viral reservoirs—the hidden stores of virus in the body—were likely smaller. It remains to be seen whether this approach will work as well in patients with larger or more established viral reservoirs.

The bigger questions ahead involve whether the engineered cells will last long-term in the body, how to ensure they spread effectively to where the virus hides, and whether this approach will help a broad range of HIV patients or only certain groups.

Worth noting: CAR-T therapies, which borrow this same immunological strategy, already transformed treatment for some blood cancers. Several research groups are now betting that the same fundamental approach can work for a persistent viral infection—a shift in how we might control or even functionally cure HIV. These early reports suggest the science is mature enough to try.